Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AMLJoshua F. Zeidner, Alice S. Mims, Rina Li Welkie et al.|Journal of Clinical Oncology|2025Cited by 36